[go: up one dir, main page]

PE20040997A1 - Compuestos aromaticos heterociclicos referidos a secretagogos de la hormona del crecimiento - Google Patents

Compuestos aromaticos heterociclicos referidos a secretagogos de la hormona del crecimiento

Info

Publication number
PE20040997A1
PE20040997A1 PE2003000897A PE2003000897A PE20040997A1 PE 20040997 A1 PE20040997 A1 PE 20040997A1 PE 2003000897 A PE2003000897 A PE 2003000897A PE 2003000897 A PE2003000897 A PE 2003000897A PE 20040997 A1 PE20040997 A1 PE 20040997A1
Authority
PE
Peru
Prior art keywords
secretagogs
growth hormone
aromatic compounds
alkyl
heterocyclic aromatic
Prior art date
Application number
PE2003000897A
Other languages
English (en)
Inventor
Guixue Yu
James J Li
Jun Li
Joseph A Tino
Richard B Sulsky
William R Ewing
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31981567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040997(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040997A1 publication Critical patent/PE20040997A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Xa ES DE 2-4 ANILLOS FUSIONADOS, ESPIRO HETEROARILO, ARILO, HETEROCICLO, ENTRE OTROS; R1 ES ALQUILO, ARILO, ALQUENILO, ARILALQUILO, ENTRE OTROS; R2, R3 Y R4 SON CADA UNO H, ALQUILO, ALQUENILO, ARILO, CICLOALQUILO, ENTRE OTROS; R1' ES H, ALQUILO, CICLOALQUILO, HETEROARILO, ENTRE OTROS; Y ES ALQUILENO, ALQUENILENO, ARILENO, ENTRE OTROS; Z ES N; n ES 1-6. SON COMPUESTOS PREFERIDOS: 2-AMINO-N-[1-(6-BROMO-[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-IL)-3-FENIL-PROPIL]-2-METIL-PROPIONAMIDA; 2-AMINO-2-METIL-N-[3-FENIL-1-(6-TRIFLUOROMETIL-[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-IL)-PROPIL]-PROPIONAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE LA OBESIDAD, OSTEROPOROSIS Y EN LA MEJORA DE LA MASA Y FUERZA MUSCULAR
PE2003000897A 2002-09-04 2003-09-04 Compuestos aromaticos heterociclicos referidos a secretagogos de la hormona del crecimiento PE20040997A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40809902P 2002-09-04 2002-09-04
US49164503P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
PE20040997A1 true PE20040997A1 (es) 2005-01-12

Family

ID=31981567

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000897A PE20040997A1 (es) 2002-09-04 2003-09-04 Compuestos aromaticos heterociclicos referidos a secretagogos de la hormona del crecimiento

Country Status (30)

Country Link
US (8) US7166596B2 (es)
EP (2) EP2570414B1 (es)
JP (1) JP4658600B2 (es)
KR (3) KR101238041B1 (es)
CN (2) CN1678372A (es)
AR (1) AR041143A1 (es)
AU (1) AU2003270065B2 (es)
BR (1) BR0314024A (es)
CA (1) CA2496842C (es)
CY (2) CY1120250T1 (es)
DK (2) DK1551511T5 (es)
ES (2) ES2706578T3 (es)
GE (1) GEP20074019B (es)
HR (1) HRP20050188B1 (es)
HU (2) HUE041936T2 (es)
IL (5) IL166802A (es)
IS (1) IS7719A (es)
LT (2) LT2570414T (es)
MX (1) MXPA05002301A (es)
MY (1) MY139563A (es)
NO (1) NO332370B1 (es)
NZ (1) NZ538166A (es)
PE (1) PE20040997A1 (es)
PL (1) PL219563B1 (es)
PT (2) PT2570414T (es)
RS (2) RS20050186A (es)
RU (1) RU2382042C2 (es)
SI (2) SI1551511T1 (es)
TW (2) TWI362389B (es)
WO (1) WO2004021984A2 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AR043443A1 (es) * 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
AU2005272627A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
US20080261873A1 (en) * 2004-08-18 2008-10-23 Elixir Pharmaceuticals, Inc. Growth-Hormone Secretagogues
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006036932A2 (en) * 2004-09-27 2006-04-06 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
CA2611493A1 (en) * 2005-06-10 2006-12-21 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
JP5292102B2 (ja) 2005-12-21 2013-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チロシンキナーゼ調節剤としてのトリアゾロピリダジン類
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2004643A1 (en) * 2006-03-31 2008-12-24 Novartis AG Organic compounds
EP2046788A1 (en) * 2006-07-12 2009-04-15 Syngeta Participations AG Triazolopyridine derivatives as herbicides
UA99448C2 (en) 2006-11-27 2012-08-27 Х. Луннбэк А/С Heteroaryl amide derivatives
EP2119719A1 (en) * 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
MX2009010523A (es) 2007-04-10 2009-12-15 Lundbeck & Co As H Análogos de amidas heteroarílicas como antagonistas de p2x7.
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
CA2689989A1 (en) * 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
DK2203439T3 (da) 2007-09-14 2011-04-18 Ortho Mcneil Janssen Pharm 1',3'-disubstituerede 4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']-bipyridinyl-2'-oner
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010050445A1 (ja) * 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO2907B1 (en) 2009-05-12 2015-09-15 اديكس فرما اس ايه Pyridine derivatives 1, 2, 4 trisolo [4, 3-A] and their uses as positive LLs for 2MGLUR receptors
US8592590B2 (en) 2009-12-29 2013-11-26 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
PT2552920T (pt) 2010-04-02 2017-06-07 Ogeda Sa Compostos antagonistas seletivos de recetor de nk-3 inovadores, composições farmacêuticas e métodos para utilização em distúrbios mediados por recetores de nk-3
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
EP2446898A1 (en) * 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2763992B9 (en) 2011-10-03 2016-08-24 Euroscreen S.A. Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20140287997A1 (en) * 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Use of growth hormone or growth hormone receptor agonists to prevent or treat stress-sensitive psychiatric illness
SI2948455T1 (sl) 2013-03-29 2017-12-29 Ogeda S.A. N-acil-(3-substituiran) - (8-substituiran) -5,6-dihidro- (1,2,4) triazolo (4,3-a) pirazini kot selektivni antagonist receptor nk-3, farmacevtski sestavek, postopki za uporabo v nk-3 receptor mediiranih motnjah
AU2014242908B2 (en) 2013-03-29 2018-07-19 Ogeda Sa Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
JP6275241B2 (ja) 2013-03-29 2018-02-07 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−５，６，７，８−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
WO2016046398A1 (en) 2014-09-25 2016-03-31 Euroscreen Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
TW201629064A (zh) * 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
EP3239150B1 (en) * 2014-12-24 2020-02-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
KR102784592B1 (ko) 2015-08-12 2025-03-19 에피제네틱스, 인크. 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US10519151B2 (en) * 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
CN111533745A (zh) * 2020-05-20 2020-08-14 成都药明康德新药开发有限公司 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法
CN112608315B (zh) * 2020-12-14 2021-11-30 承德医学院 三唑并二氮杂卓类化合物及其制备方法及医药用途
JP2024528885A (ja) * 2021-08-13 2024-08-01 エムペセ テラピューティクス エスアー がんの治療における使用のための、ミトコンドリアのピルビン酸輸送体阻害剤としての［１，２，４］トリアゾロ［４，３－ａ］ピリミジン－７（８Ｈ）－オン
WO2025090941A1 (en) * 2023-10-27 2025-05-01 The Regents Of The University Of California Calcium sensing receptor modulators and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050525A (en) * 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
GB1586468A (en) * 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1258790B (it) * 1992-01-17 1996-02-29 Angelini Francesco Ist Ricerca Alchil derivati del trazodone
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
EP0730578A4 (en) 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING INDOLYL GROUPS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONES
DE4404183A1 (de) * 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
DK0760819T3 (da) * 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ATE272069T1 (de) 1995-01-27 2004-08-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU715856B2 (en) * 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
CN1188409C (zh) 1997-09-05 2005-02-09 立德化学株式会社 立体异构吲哚化合物、其制备方法及用途
US6114310A (en) * 1998-01-23 2000-09-05 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
DE1071701T1 (de) * 1998-04-14 2001-08-23 Arena Pharmaceuticals, Inc. Non-endogene, konstitutiv aktivierte humane serotonin-rezeptoren und kleine molekülmodulatoren davon
US6852725B1 (en) 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
ATE416772T1 (de) 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
RU2240998C2 (ru) 1998-12-04 2004-11-27 Бристол-Маерс Сквибб Компани Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US20050148018A1 (en) * 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
PL363316A1 (en) * 2000-12-22 2004-11-15 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
KR100974901B1 (ko) * 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
ES2367135T3 (es) * 2003-01-16 2011-10-28 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.
RU2417986C2 (ru) * 2004-09-27 2011-05-10 Акадиа Фармасьютикалз Инк. Синтез n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n'-(4-(2-метилпропилокси)фенилметил)карбамида, а также его тартрата и кристаллических форм
EP2004643A1 (en) * 2006-03-31 2008-12-24 Novartis AG Organic compounds

Also Published As

Publication number Publication date
NO20050748L (no) 2005-03-30
HRP20050188A2 (en) 2005-12-31
MXPA05002301A (es) 2005-06-08
TW201030004A (en) 2010-08-16
HUE035498T2 (en) 2018-05-02
IL166802A (en) 2011-06-30
IL210823A (en) 2017-07-31
IL211281A (en) 2017-11-30
RU2005109545A (ru) 2006-01-10
US20100305114A1 (en) 2010-12-02
IL210823A0 (en) 2011-04-28
HUE041936T2 (hu) 2019-06-28
US8232291B2 (en) 2012-07-31
TW200410969A (en) 2004-07-01
SI2570414T1 (sl) 2017-10-30
US20040147568A1 (en) 2004-07-29
EP2570414B1 (en) 2017-08-30
RU2382042C2 (ru) 2010-02-20
WO2004021984A2 (en) 2004-03-18
AR041143A1 (es) 2005-05-04
RS55124B1 (sr) 2016-12-30
GEP20074019B (en) 2007-01-10
US20060079549A1 (en) 2006-04-13
BR0314024A (pt) 2005-07-19
CY1120250T1 (el) 2019-07-10
JP2006502162A (ja) 2006-01-19
KR101238041B1 (ko) 2013-02-27
US7592354B2 (en) 2009-09-22
US7977353B2 (en) 2011-07-12
MY139563A (en) 2009-10-30
EP1551511B1 (en) 2018-10-24
PL219563B1 (pl) 2015-05-29
US8557841B2 (en) 2013-10-15
PT2570414T (pt) 2017-10-30
KR20110053494A (ko) 2011-05-23
US7799801B2 (en) 2010-09-21
CY1121201T1 (el) 2020-05-29
AU2003270065A1 (en) 2004-03-29
EP1551511A2 (en) 2005-07-13
CN1678372A (zh) 2005-10-05
LT2570414T (lt) 2017-11-27
TWI330185B (en) 2010-09-11
SI1551511T1 (sl) 2019-02-28
IL166802A0 (en) 2006-01-15
ES2644265T3 (es) 2017-11-28
EP1551511A4 (en) 2006-08-23
IL210824A0 (en) 2011-04-28
NO332370B1 (no) 2012-09-03
US7589102B2 (en) 2009-09-15
IL191960A (en) 2015-11-30
PL375882A1 (en) 2005-12-12
CN101863886A (zh) 2010-10-20
AU2003270065B2 (en) 2008-06-05
KR20110003592A (ko) 2011-01-12
CA2496842C (en) 2011-02-15
NZ538166A (en) 2007-01-26
EP2570414A1 (en) 2013-03-20
US7910601B2 (en) 2011-03-22
HRP20050188B1 (hr) 2019-03-08
US20100016233A1 (en) 2010-01-21
ES2706578T3 (es) 2019-03-29
PT1551511T (pt) 2019-01-29
JP4658600B2 (ja) 2011-03-23
DK1551511T5 (da) 2019-11-11
DK2570414T3 (en) 2017-12-04
US20120252799A1 (en) 2012-10-04
US20060063798A1 (en) 2006-03-23
US20110224199A1 (en) 2011-09-15
US20090324625A1 (en) 2009-12-31
KR20050040933A (ko) 2005-05-03
WO2004021984A3 (en) 2004-11-25
IS7719A (is) 2005-02-28
TWI362389B (en) 2012-04-21
IL191960A0 (en) 2008-12-29
LT1551511T (lt) 2018-12-27
DK1551511T3 (en) 2019-02-18
US7166596B2 (en) 2007-01-23
CA2496842A1 (en) 2004-03-18
RS20050186A (sr) 2007-11-15

Similar Documents

Publication Publication Date Title
PE20040997A1 (es) Compuestos aromaticos heterociclicos referidos a secretagogos de la hormona del crecimiento
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
Leurs et al. The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor
ES2626036T3 (es) Antagonista del receptor P2X4
PE20040680A1 (es) Inhibidores novedosos de cinasas
DE60013250D1 (en) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
PE20011258A1 (es) Derivados de benzocicloalquilenilamina como antagonistas de receptores muscarinicos
WO2005044793A3 (en) Nitrogen-containing fused heterocyclic compounds
RU2003127734A (ru) Ингибиторы металлопротеиназ
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
DE60023318D1 (de) Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
CO5580778A2 (es) Derivados de lactama como antagonistas para receptores 11cby humanos
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
UY26056A1 (es) Compuestos heterociclicos aromaticos utiles como secretagogos de la hormona del crecimiento
TW200615267A (en) New bicyclic antibiotics
DE602005013248D1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CN1394857A (zh) 用作抗增殖剂和甘氨酰胺核糖核苷酸甲酰转移酶抑制剂的化合物
CA2468658A1 (en) [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
PE20011325A1 (es) Heterociclilalquilaminas como antagonistas de los receptores muscarinicos
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration